Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

FDA Approval Summary: Tagraxofusp-erzs For Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
Emily Y. Jen, Xin Gao, Liang Li, et al.
Clinical Cancer Research (2019) Vol. 26, Iss. 3, pp. 532-536
Open Access | Times Cited: 80

Showing 1-25 of 80 citing articles:

Drug conjugates for targeting regulatory T cells in the tumor microenvironment: guided missiles for cancer treatment
Juwon Yang, Hyunsu Bae
Experimental & Molecular Medicine (2023) Vol. 55, Iss. 9, pp. 1996-2004
Open Access | Times Cited: 25
Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm
Naveen Pemmaraju, Marina Konopleva
Blood Advances (2020) Vol. 4, Iss. 16, pp. 4020-4027
Open Access | Times Cited: 58
Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm
Naveen Pemmaraju, Kendra Sweet, Anthony S. Stein, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 26, pp. 3032-3036
Open Access | Times Cited: 32
North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need
Naveen Pemmaraju, Hagop M. Kantarjian, Kendra Sweet, et al.
Blood (2022) Vol. 141, Iss. 6, pp. 567-578
Open Access | Times Cited: 31
Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia
Andrew A. Lane, Jacqueline S. Garcia, Evangeline G. Raulston, et al.
Blood Advances (2023) Vol. 8, Iss. 3, pp. 591-602
Open Access | Times Cited: 19
A perspective of immunotherapy for acute myeloid leukemia: Current advances and challenges
Ying Chen, Jishi Wang, Fengqi Zhang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 14
Efficacy and manageable safety of tagraxofusp in blastic plasmacytoid dendritic cell neoplasm: a case series of pediatric and adolescent/young adult patients
Naveen Pemmaraju, Branko Cuglievan, Joseph A. Lasky, et al.
eJHaem (2024) Vol. 5, Iss. 1, pp. 61-69
Open Access | Times Cited: 5
Blastic plasmacytoid dendritic cell neoplasm: diagnosis, manifestations, and treatment
Kendra Sweet
Current Opinion in Hematology (2020) Vol. 27, Iss. 2, pp. 103-107
Closed Access | Times Cited: 37
An engineered chimeric toxin that cleaves activated mutant and wild-type RAS inhibits tumor growth
Vania Vidimar, Greg L. Beilhartz, Minyoung Park, et al.
Proceedings of the National Academy of Sciences (2020) Vol. 117, Iss. 29, pp. 16938-16948
Open Access | Times Cited: 34
Therapeutic Fusion Proteins
Morgan C. Marsh, Shawn C. Owen
The AAPS Journal (2023) Vol. 26, Iss. 1
Closed Access | Times Cited: 11
Tagraxofusp, a first‐in‐class CD123‐targeted agent: Five‐year postapproval comprehensive review of the literature
Wei‐Ying Jen, Marina Konopleva, Naveen Pemmaraju
Cancer (2024) Vol. 130, Iss. 13, pp. 2260-2271
Closed Access | Times Cited: 4
Escherichia coli in the production of biopharmaceuticals
İbrahim İncir, Özlem Kaplan
Biotechnology and Applied Biochemistry (2024)
Open Access | Times Cited: 4
New and Emerging Targeted Therapies for Pediatric Acute Myeloid Leukemia (AML)
Jing Chen, Chana L. Glasser
Children (2020) Vol. 7, Iss. 2, pp. 12-12
Open Access | Times Cited: 32
Immunotoxins and nanobody-based immunotoxins: review and update
Mohammad Reza Khirehgesh, Jafar Sharifi, Fatemeh Safari, et al.
Journal of drug targeting (2021) Vol. 29, Iss. 8, pp. 848-862
Closed Access | Times Cited: 27
Vaccination Therapy for Acute Myeloid Leukemia: Where Do We Stand?
Kordelia Barbullushi, Nicolò Rampi, Fabio Serpenti, et al.
Cancers (2022) Vol. 14, Iss. 12, pp. 2994-2994
Open Access | Times Cited: 18
Blastic plasmacytoid dendritic cell neoplasm (BPDCN): A promising future in the era of targeted therapeutics
Ijele Adimora, Nathaniel R. Wilson, Naveen Pemmaraju
Cancer (2022) Vol. 128, Iss. 16, pp. 3019-3026
Closed Access | Times Cited: 17
A new treatment for canine B-cell lymphoma based on a recombinant single-domain antibody immunotoxin derived from Pseudomonas aeruginosa exotoxin A
A André, Joana Dias, Isa Moutinho, et al.
Frontiers in Veterinary Science (2025) Vol. 12
Open Access
A Novel Antibody-Drug Conjugate (ADC) Delivering a DNA Mono-Alkylating Payload to Chondroitin Sulfate Proteoglycan (CSPG4)-Expressing Melanoma
Ricarda M. Hoffmann, Silvia Crescioli, Silvia Mele, et al.
Cancers (2020) Vol. 12, Iss. 4, pp. 1029-1029
Open Access | Times Cited: 27
Selective delivery of T22-PE24-H6 to CXCR4+ diffuse large B-cell lymphoma cells leads to wide therapeutic index in a disseminated mouse model
Aïda Falgàs, Víctor Pallarès, Naroa Serna, et al.
Theranostics (2020) Vol. 10, Iss. 12, pp. 5169-5180
Open Access | Times Cited: 25
SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells
Siret Tahk, Binje Vick, Björn Hiller, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 22
Antineoplastic effect of a diphtheria toxin-based nanoparticle targeting acute myeloid leukemia cells overexpressing CXCR4
Víctor Pallarès, Yáiza Núñez, Laura Sánchez‐García, et al.
Journal of Controlled Release (2021) Vol. 335, pp. 117-129
Closed Access | Times Cited: 21
Acute Myeloid Leukemia in Older Patients: From New Biological Insights to Targeted Therapies
Pasquale Niscola, Valentina Gianfelici, Gianfranco Catalano, et al.
Current Oncology (2024) Vol. 31, Iss. 11, pp. 6632-6658
Open Access | Times Cited: 3
Use of Exogenous Enzymes in Human Therapy: Approved Drugs and Potential Applications
Patrizia Cioni, Edi Gabellieri, Barbara Campanini, et al.
Current Medicinal Chemistry (2021) Vol. 29, Iss. 3, pp. 411-452
Closed Access | Times Cited: 20
Translating the biology of β common receptor-engaging cytokines into clinical medicine
Harshita Pant, Timothy R. Hercus, Damon J. Tumes, et al.
Journal of Allergy and Clinical Immunology (2022) Vol. 151, Iss. 2, pp. 324-344
Open Access | Times Cited: 14
Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm
Marlise R. Luskin, Andrew A. Lane
Haematologica (2023)
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top